Peptide Longevity Q&A ·
Research indicates that circulating levels of MOTS-c are significantly higher in obese individuals compared to lean counterparts, suggesting a role in metabolic dysregulation. However, these levels do not change after weight loss, indicating a potential compensatory mechanism in obesity and insulin resistance.
What the research shows
The study explored the relationship between circulating MOTS-c levels and metabolic health in adults with obesity compared to lean controls. It involved 22 lean participants and 32 obese individuals scheduled for bariatric surgery. The researchers measured circulating MOTS-c levels, metabolic parameters, and inflammatory markers. Additionally, longitudinal changes in these parameters were assessed in 10 of the obese patients before and six months after bariatric surgery. The study also examined adipose tissue MOTS-c expression through immunofluorescence analysis in lean kidney donors and obese subjects.
Why it matters for longevity
The findings suggest that elevated MOTS-c levels in obesity may reflect a compensatory metabolic response to altered metabolic and inflammatory states. Understanding the role of MOTS-c in obesity and insulin resistance is crucial for developing potential interventions to improve metabolic health and extend healthspan. Given that MOTS-c levels remain unchanged after significant weight loss, further research is needed to clarify its role and potential as a clinical biomarker in metabolic disorders.
Key findings at a glance
- Circulating MOTS-c levels are significantly higher in obese individuals (273 ± 56 pg/mL) compared to lean individuals (223 ± 50 pg/mL).
- Body Mass Index (BMI) and HOMA-IR independently predicted elevated MOTS-c levels.
- MOTS-c levels showed a nonlinear relationship with HOMA-IR, increasing sharply above a certain threshold.
- Despite significant BMI improvements post-bariatric surgery, circulating MOTS-c levels remained unchanged.
- Adipose tissue MOTS-c expression did not differ significantly between lean and obese groups.
How MOTS-c works (background)
MOTS-c is a mitochondrial-derived peptide that plays a role in regulating metabolic homeostasis. It is involved in glucose and lipid metabolism, and its increased levels in obesity may indicate a response to metabolic dysregulation. The peptide's relationship with insulin resistance and its potential role in metabolic pathways highlight its importance in understanding obesity and related conditions.
Safety, caveats, and what we don't yet know
This study presents preliminary findings that warrant further validation in larger, independent cohorts. The sample size was relatively small, and the study focused on specific populations (obese individuals scheduled for bariatric surgery). Future research should explore the implications of MOTS-c in diverse populations and its potential therapeutic applications.
Bottom line
In summary, circulating MOTS-c levels are elevated in obesity and do not change after weight loss, suggesting a compensatory role in metabolic dysregulation. This highlights the need for further research to understand its implications for metabolic health and longevity.
Related questions
Can MOTS-c support mitochondrial function in aging muscle tissue?
Research indicates that mitochondrial-derived peptides like MOTS-c may play a role in maintaining mitochondrial function, which is crucial for muscle health as individuals age. However, specific studies focusing on aging muscle tissue are needed to draw definitive conclusions.
Does MOTS-c reduce inflammaging in older adults?
While MOTS-c has been associated with metabolic regulation, its direct impact on reducing inflammation associated with aging (inflammaging) requires further investigation. Current research primarily focuses on its role in obesity and metabolic health.
What is the role of MOTS-c in metabolic disorders?
MOTS-c appears to be involved in metabolic homeostasis and may serve as a biomarker for metabolic disorders. Its elevated levels in obesity suggest a potential connection to insulin resistance, warranting further research into its role in various metabolic conditions.
Source: PubMed · J Clin Transl Endocrinol · published 2026-02-01.